 |
|
|
| |
Once-daily NS5A Inhibitor (BMS-790052) Plus Peginterferon-alpha-2a And Ribavirin Produces High Rates Of Extended Rapid Virologic Response In Treatment-naïve HCV-genotype 1 Subjects: Phase 2a Trial - Bristol-Myers Squibb Study AI444014
|
| |
| |
Reported by Jules Levin
EASL, The International Liver Congress, Vienna, Austria, 2010 Apr 17,
Late-breaker Presentation
S. Pol, G. Everson, R. Ghalib, V. Rustgi, C. Martorell, H. Tatum, J. Lim, C. Hezode,
U. Diva, P.D. Yin, and R. Hindes
* Related to study regimen
|
| |
|
|
|
|
|
